ORKA
NASDAQOruka Therapeutics Inc.
$109.78+5.33 (+5.10%)
Oruka Therapeutics Inc. (ORKA) is a Biotechnology: In Vitro & In Vivo Diagnostic Substances company listed on NASDAQ. In the last 30 days Quantisnow tracked 10 wire items for ORKA, including 4 insider trades, 3 earnings updates and 2 SEC filings. The most recent was published Nov 9, 2026.
ORKA rankings
Price$109.78+5.33 (+5.10%)
02:30 PM08:45 PM
Financial highlights
Full financials- Net income, TTM
- -$152.57M
- Free cash flow, TTM
- -$123.86M
- Cash
- $191.52M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks57+33%
2026-05-172026-11-08
Mix3290d
- Insider19(59%)
- SEC Filings6(19%)
- Other3(9%)
- Earnings3(9%)
- Leadership1(3%)
Activity · 52 weeks10861 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- PROruka Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateEVERLAST-B Week 16 results showed 61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose group, highly consistent with EVERLAST-A EVERLAST-A responses continued to deepen to 71% PASI 100 at Week 28, 6 months after last dose EVERLAST-A 52-week data expected in December 2026; Phase 3 program on track to begin 1H 2027 ORKA-002 ORCA-SURGE Phase 2 enrollment completed with Week 16 data in psoriasis expected in 1Q 2027 MENLO PARK, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO)
- SECSEC Form 10-Q filed by Oruka Therapeutics Inc.10-Q - Oruka Therapeutics, Inc. (0000907654) (Filer)
- PROruka Therapeutics to Participate in Multiple Upcoming ConferencesMENLO PARK, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis and hidradenitis suppurativa, today announced its participation and presentation at multiple upcoming conferences: Guggenheim 3rd Annual Healthcare Innovation ConferenceDate: November 10, 2026Presentation Time: 11:00 AM EST Stifel 2026 Healthcare ConferenceDate: November 11, 2026Presentation Time: 4:00 PM EST UBS Global Biopharma ConferenceDate: November 17, 2026Presentation Time: 4:00 PM GMT Jefferies Global Healthcare
- INSIDERChief Executive Officer Klein Lawrence Otto exercised 25,000 shares at a strike of $7.80 and sold $2,390,125 worth of shares (25,000 units at $95.60) as part of a pre-agreed trading plan (SEC Form 4)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- SECSEC Form 8-K filed by Oruka Therapeutics Inc.8-K - Oruka Therapeutics, Inc. (0000907654) (Filer)
- PROruka Therapeutics Announces Positive Week 16 Results for ORKA-001 from the Ongoing EVERLAST-B Trial in Moderate-to-Severe Psoriasis61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose (600 mg) group, highly similar to EVERLAST-A Continued favorable safety and tolerability profile consistent with the IL-23p19 class ORKA-001 on track to advance into Phase 3 trials in 1H 2027 52-week EVERLAST-A results on track for December 2026 ORKA-002 16-week results from ORCA-SURGE Phase 2 in psoriasis on track for 1Q 2027 Management to host conference call today at 8:00 a.m. ET MENLO PARK, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (Oruka) (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseas
- PROruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026MENLO PARK, Calif., Oct. 25, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO) and hidradenitis suppurativa (HS), today announced it will report Week 16 data for ORKA-001 from the ongoing EVERLAST-B Phase 2b trial in moderate-to-severe plaque psoriasis on Monday, October 26, 2026. Following the announcement, the company will host a conference call and webcast at 8:00 a.m. ET to discuss the results. Webcast Details Oruka Therapeutics’ live webcast of the EVERLAST-B results will begin on Monday
- INSIDERGeneral Counsel Quinlan Paul T sold $706,735 worth of shares (9,000 units at $78.53) as part of a pre-agreed trading plan (SEC Form 4)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERChief Medical Officer Goncalves Joana sold $523,648 worth of shares (7,000 units at $74.81) as part of a pre-agreed trading plan (SEC Form 4)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERSenior Vice President, Finance Agarwal Arjun sold $805,889 worth of shares (9,999 units at $80.60) as part of a pre-agreed trading plan (SEC Form 4)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERChief Executive Officer Klein Lawrence Otto exercised 25,000 shares at a strike of $7.80 and sold $2,090,593 worth of shares (25,000 units at $83.62) as part of a pre-agreed trading plan (SEC Form 4)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- PROruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional DosingPASI 100 increased to 71.4% and PASI 90 increased to 87.3%, despite no dosing after Week 4 Placebo crossover patients reached PASI 100 and PASI 90 rates similar to those initially dosed with ORKA-001 ORKA-001 maintained a favorable safety and tolerability profile through Week 28 52-week EVERLAST-A data for all patients expected in December 2026 16-week EVERLAST-B data expected in 4Q 2026 MENLO PARK, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO) and hidradenitis suppura
- INSIDERSenior Vice President, Finance Agarwal Arjun sold $51,035 worth of shares (533 units at $95.75) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 14,219 units (SEC Form 4)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERGeneral Counsel Quinlan Paul T exercised 10,000 shares at a strike of $7.80 and sold $936,417 worth of shares (10,000 units at $93.64) as part of a pre-agreed trading plan (SEC Form 4)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERChief Medical Officer Goncalves Joana exercised 7,000 shares at a strike of $7.32 and sold $734,145 worth of shares (7,947 units at $92.38) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 31,771 units (SEC Form 4) (for tax liability)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERSenior Vice President, Finance Agarwal Arjun sold $926,010 worth of shares (10,019 units at $92.43) as part of a pre-agreed trading plan and exercised 9,459 shares at a strike of $15.88, decreasing direct ownership by 4% to 14,752 units (SEC Form 4) (for tax liability)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERChief Executive Officer Klein Lawrence Otto sold $234,681 worth of shares (2,452 units at $95.71), decreasing direct ownership by 0.26% to 923,128 units (SEC Form 4) to cover withholding tax4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERGeneral Counsel Quinlan Paul T sold $99,443 worth of shares (1,039 units at $95.71), decreasing direct ownership by 3% to 29,995 units (SEC Form 4) to cover withholding tax4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERChief Operating Officer Sandler Laura Lee sold $86,713 worth of shares (906 units at $95.71), decreasing direct ownership by 0.38% to 235,478 units (SEC Form 4) (withholding tax)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- PROruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare ConferenceMENLO PARK, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis and hidradenitis suppurativa, today announced its attendance at the 2026 Morgan Stanley Global Healthcare Conference, taking place in New York, NY from September 14-16, 2026.About Oruka TherapeuticsOruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from inflammatory diseases like plaque psoriasis and hidr
- INSIDERChief Operating Officer Sandler Laura Lee exercised 5,000 shares at a strike of $7.80 and sold $459,101 worth of shares (5,000 units at $91.82) as part of a pre-agreed trading plan (SEC Form 4)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERChief Executive Officer Klein Lawrence Otto exercised 75,000 shares at a strike of $7.80 and sold $6,887,484 worth of shares (75,000 units at $91.83) as part of a pre-agreed trading plan (SEC Form 4)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- SECSEC Form 424B5 filed by Oruka Therapeutics Inc.424B5 - Oruka Therapeutics, Inc. (0000907654) (Filer)
- SECSEC Form EFFECT filed by Oruka Therapeutics Inc.EFFECT - Oruka Therapeutics, Inc. (0000907654) (Filer)
- INSIDERChief Commercial Officer Edwards Larry Todd was granted 100,000 shares (SEC Form 4)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
ORKA FAQ
8 questionsWhat is the latest news on ORKA?
In the last 30 days Quantisnow tracked 10 wire items for ORKA: 4 insider trades, 3 earnings updates, 2 SEC filings and 1 press release or news item. The most recent was published on November 9, 2026.Is ORKA profitable?
No. Oruka Therapeutics Inc. reported a net loss of $152.57M for the twelve months ended Sep 30, 2026.How much cash and debt does ORKA have?
Oruka Therapeutics Inc. reported $191.52M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does ORKA stock trade?
Oruka Therapeutics Inc. (ORKA) is listed on NASDAQ.What sector and industry is ORKA in?
Oruka Therapeutics Inc. operates in the Health Care sector, Biotechnology: In Vitro & In Vivo Diagnostic Substances industry.What are analysts saying about ORKA?
Oruka Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Piper Sandler: Overweight with a $75.00 price target on 2025-12-18. Recent price targets range from $20.00 to $75.00.What companies are similar to ORKA?
Notable peers in the same industry include ACHV (Achieve Life Sciences Inc.), LNTH (Lantheus Holdings Inc.), NTLA (Intellia Therapeutics Inc.), TKNO (Alpha Teknova Inc.), CLDX (Celldex Therapeutics Inc.). Compare ORKA side-by-side with any of them on Quantisnow.How can I track ORKA on Quantisnow?
Quantisnow aggregates Oruka Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ORKA to receive live email and push alerts on every new disclosure.